Active Biotech AB (publ) (ACTI.ST)
SEK 0.11
(-7.32%)
SEK 0.11
(-7.32%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 13.4 Million SEK | -18.76% |
| 2022 | 16.49 Million SEK | 62.82% |
| 2021 | 10.13 Million SEK | 0.88% |
| 2020 | 10.04 Million SEK | -23.76% |
| 2019 | 13.17 Million SEK | -93.86% |
| 2018 | 214.51 Million SEK | -5.14% |
| 2017 | 226.13 Million SEK | -1.82% |
| 2016 | 230.32 Million SEK | -14.33% |
| 2015 | 268.83 Million SEK | -15.25% |
| 2014 | 317.21 Million SEK | -12.47% |
| 2013 | 362.39 Million SEK | 1.56% |
| 2012 | 356.81 Million SEK | 0.08% |
| 2011 | 356.52 Million SEK | 10.95% |
| 2010 | 321.33 Million SEK | 3.7% |
| 2009 | 309.85 Million SEK | 0.17% |
| 2008 | 309.33 Million SEK | 3.12% |
| 2007 | 299.97 Million SEK | -25.39% |
| 2006 | 402.04 Million SEK | 2.81% |
| 2005 | 391.05 Million SEK | 159.68% |
| 2004 | 150.58 Million SEK | 169.76% |
| 2003 | 55.82 Million SEK | -36.01% |
| 2002 | 87.23 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 13.4 Million SEK | 0.0% |
| 2024 Q3 | 13.5 Million SEK | 8.0% |
| 2024 Q2 | 12.5 Million SEK | -6.72% |
| 2023 FY | 13.4 Million SEK | -18.76% |
| 2023 Q1 | 16.5 Million SEK | 0.04% |
| 2023 Q3 | 13 Million SEK | 2.36% |
| 2023 Q2 | 12.7 Million SEK | -23.03% |
| 2023 Q4 | 13.4 Million SEK | 3.08% |
| 2022 Q4 | 16.49 Million SEK | 0.57% |
| 2022 Q2 | 15.9 Million SEK | 40.71% |
| 2022 Q1 | 11.3 Million SEK | 11.55% |
| 2022 FY | 16.49 Million SEK | 62.82% |
| 2022 Q3 | 16.4 Million SEK | 3.14% |
| 2021 Q1 | 10.6 Million SEK | 5.56% |
| 2021 Q2 | 9.1 Million SEK | -14.15% |
| 2021 Q4 | 10.13 Million SEK | 2.32% |
| 2021 Q3 | 9.9 Million SEK | 8.79% |
| 2021 FY | 10.13 Million SEK | 0.88% |
| 2020 Q4 | 10.04 Million SEK | -0.57% |
| 2020 FY | 10.04 Million SEK | -23.76% |
| 2020 Q1 | 10.5 Million SEK | -20.28% |
| 2020 Q2 | 10.1 Million SEK | -3.81% |
| 2020 Q3 | 10.1 Million SEK | 0.0% |
| 2019 Q2 | 9.6 Million SEK | -95.51% |
| 2019 Q4 | 13.17 Million SEK | -5.24% |
| 2019 FY | 13.17 Million SEK | -93.86% |
| 2019 Q1 | 213.9 Million SEK | -0.29% |
| 2019 Q3 | 13.9 Million SEK | 44.79% |
| 2018 Q2 | 218.3 Million SEK | -2.59% |
| 2018 Q1 | 224.1 Million SEK | -0.9% |
| 2018 Q3 | 216.5 Million SEK | -0.82% |
| 2018 Q4 | 214.51 Million SEK | -0.92% |
| 2018 FY | 214.51 Million SEK | -5.14% |
| 2017 Q2 | 233.1 Million SEK | 1.79% |
| 2017 Q4 | 226.13 Million SEK | -0.99% |
| 2017 FY | 226.13 Million SEK | -1.82% |
| 2017 Q1 | 229 Million SEK | -0.57% |
| 2017 Q3 | 228.4 Million SEK | -2.02% |
| 2016 Q1 | 242 Million SEK | -9.98% |
| 2016 FY | 230.32 Million SEK | -14.33% |
| 2016 Q3 | 232.6 Million SEK | -3.73% |
| 2016 Q2 | 241.6 Million SEK | -0.17% |
| 2016 Q4 | 230.32 Million SEK | -0.98% |
| 2015 FY | 268.83 Million SEK | -15.25% |
| 2015 Q4 | 268.83 Million SEK | 2.06% |
| 2015 Q3 | 263.4 Million SEK | -10.77% |
| 2015 Q2 | 295.2 Million SEK | -5.14% |
| 2015 Q1 | 311.2 Million SEK | -1.9% |
| 2014 Q2 | 326.9 Million SEK | -4.78% |
| 2014 Q4 | 317.21 Million SEK | 1.22% |
| 2014 Q3 | 313.4 Million SEK | -4.13% |
| 2014 Q1 | 343.3 Million SEK | -5.27% |
| 2014 FY | 317.21 Million SEK | -12.47% |
| 2013 Q4 | 362.39 Million SEK | 9.35% |
| 2013 Q3 | 331.4 Million SEK | 2.19% |
| 2013 FY | 362.39 Million SEK | 1.56% |
| 2013 Q1 | 331.5 Million SEK | -7.1% |
| 2013 Q2 | 324.3 Million SEK | -2.17% |
| 2012 Q4 | 356.81 Million SEK | -3.27% |
| 2012 Q1 | 364.6 Million SEK | 2.26% |
| 2012 Q2 | 393.2 Million SEK | 7.84% |
| 2012 FY | 356.81 Million SEK | 0.08% |
| 2012 Q3 | 368.9 Million SEK | -6.18% |
| 2011 Q1 | 297.1 Million SEK | -7.54% |
| 2011 Q2 | 319.3 Million SEK | 7.47% |
| 2011 Q3 | 326 Million SEK | 2.1% |
| 2011 Q4 | 356.52 Million SEK | 9.36% |
| 2011 FY | 356.52 Million SEK | 10.95% |
| 2010 Q4 | 321.33 Million SEK | 7.36% |
| 2010 FY | 321.33 Million SEK | 3.7% |
| 2010 Q2 | 302.6 Million SEK | 0.4% |
| 2010 Q1 | 301.4 Million SEK | -2.73% |
| 2010 Q3 | 299.3 Million SEK | -1.09% |
| 2009 FY | 309.85 Million SEK | 0.17% |
| 2009 Q4 | 309.85 Million SEK | 0.0% |
| 2008 FY | 309.33 Million SEK | 3.12% |
| 2007 FY | 299.97 Million SEK | -25.39% |
| 2006 FY | 402.04 Million SEK | 2.81% |
| 2005 FY | 391.05 Million SEK | 159.68% |
| 2004 FY | 150.58 Million SEK | 169.76% |
| 2003 FY | 55.82 Million SEK | -36.01% |
| 2002 FY | 87.23 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 87.429% |
| Ziccum AB (publ) | 6.38 Million SEK | -109.768% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -468.037% |
| BioArctic AB (publ) | 139.5 Million SEK | 90.394% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | 61.275% |
| Mendus AB (publ) | 51.22 Million SEK | 73.841% |
| Genovis AB (publ.) | 98.04 Million SEK | 86.333% |
| Intervacc AB (publ) | 21.68 Million SEK | 38.192% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | 49.828% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 89.192% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | 16.858% |
| Aptahem AB (publ) | 8.99 Million SEK | -48.925% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | 67.204% |
| Kancera AB (publ) | 17.97 Million SEK | 25.464% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | 70.983% |
| Fluicell AB (publ) | 8.91 Million SEK | -50.308% |
| Saniona AB (publ) | 86.08 Million SEK | 84.434% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -159.791% |
| Biovica International AB (publ) | 34.76 Million SEK | 61.458% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | -14.844% |
| AcouSort AB (publ) | 10.37 Million SEK | -29.119% |
| Xintela AB (publ) | 14.01 Million SEK | 4.388% |
| Abliva AB (publ) | 16.78 Million SEK | 20.148% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 93.756% |
| Karolinska Development AB (publ) | 11.56 Million SEK | -15.827% |
| OncoZenge AB (publ) | 1.69 Million SEK | -688.699% |
| Amniotics AB (publ) | 10.54 Million SEK | -27.05% |
| 2cureX AB (publ) | 2.93 Million SEK | -356.559% |
| CombiGene AB (publ) | 4.15 Million SEK | -222.425% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -202.756% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 99.144% |
| Camurus AB (publ) | 414.81 Million SEK | 96.77% |
| Corline Biomedical AB | 6.78 Million SEK | -97.378% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 78.161% |
| Isofol Medical AB (publ) | 19.16 Million SEK | 30.077% |
| I-Tech AB | 16.2 Million SEK | 17.309% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 98.87% |
| Cyxone AB (publ) | 4.69 Million SEK | -185.471% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | -0.54% |
| Biosergen AB | 5.08 Million SEK | -163.52% |
| Cantargia AB (publ) | 54.97 Million SEK | 75.623% |
| NextCell Pharma AB | 13.68 Million SEK | 2.112% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 81.35% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | 2.698% |
| Nanologica AB (publ) | 79.32 Million SEK | 83.108% |
| SynAct Pharma AB | 51.83 Million SEK | 74.148% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -68.575% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -157.943% |
| LIDDS AB (publ) | 3.75 Million SEK | -256.763% |
| Lipum AB (publ) | 7.53 Million SEK | -77.766% |
| BioInvent International AB (publ) | 90.45 Million SEK | 85.186% |
| Alzinova AB (publ) | 9.33 Million SEK | -43.607% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 92.621% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -646.934% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | 27.544% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -249.14% |
| Simris Alg AB (publ) | 148.93 Million SEK | 91.003% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 81.158% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 97.221% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | -5.148% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -84.573% |